AINEX says it has agreed to supply its ENAD computer-aided endoscopy system to Singapore’s National University Hospital and to expand joint research with the hospital. The company says deployment is planned across NUH endoscopy units. This is a procurement and implementation signal, not yet a report of routine clinical outcomes after deployment. The distinction matters because a selected system can still face integration, adoption and monitoring work before it delivers measurable benefit at scale.
The company announcement also cites a prospective multicentre randomised trial involving 998 patients and reports that adenoma detection rose from 36.1 per cent in the control group to 52.3 per cent with ENAD. Those figures are issuer-reported descriptions of a study, and the methodology should remain attached whenever they are repeated: prospective, multicentre, randomised and 998 patients, according to AINEX. They should not be converted into a claim that every hospital, clinician or patient population will see the same result. Singapore HSA medical-device regulatory system maturity announcement
AINEX says ENAD received Singapore Health Sciences Authority approval in April 2025. Separately, HSA reported in March 2026 that Singapore had reached maturity level four for its medical-device regulatory system under the World Health Organization benchmarking framework. That official context supports confidence in the national regulatory system, but it is not an endorsement of ENAD, AINEX or the NUH procurement. Product approval, hospital selection and clinical performance are related but distinct forms of evidence.
For hospital innovation and procurement leaders in Southeast Asia, the commercially useful questions begin after selection. Teams need to test compatibility with existing endoscopy equipment, latency, alert quality, clinician training, cybersecurity, maintenance, data handling and the process for reporting adverse events. They also need a baseline against which detection rates, procedure time, false alerts and clinician acceptance can be measured. A deployment without a monitoring plan can produce activity without producing reliable operational evidence.
NUH’s planned deployment gives AINEX an important reference environment in a sophisticated health system, and it may help other hospitals assess the product. It does not remove the need for local validation, contracting and governance in each market. Buyers should ask for the full study publication, the applicable device registration record, a deployment architecture and post-market evidence. The near-term practical business indicator is therefore movement from trial evidence toward operational use; durable clinical and economic value remains something the deployment must demonstrate.
Source note
Read the official announcement for the underlying details.